I specialize in treating copd and seek therapies that optimize lung function, minimize exacerbations, and are supported by strong clinical evidence. what clinical trials have been conducted on stiolto?

Stiolto Respimat is tiotropium/olodaterol (LAMA/LABA). Because it’s a combination, the strongest “clinical trial evidence” is largely concentrated in Phase 3 efficacy/safety programs and then follow-on studies that look at symptoms, lung function, exacerbations, and longer-term outcomes.

Below are the key clinical trials/programs that have been conducted on Stiolto (tiotropium/olodaterol) and the COPD endpoints they’re known for.

1) Phase 3 program: OTIO / TONADO (major efficacy & exacerbation trials)

TONADO 1 and TONADO 2

• Design: Phase 3, randomized, double-blind, parallel-group studies
• Population: COPD patients
• Comparators: Stiolto (commonly 5/5 mcg or similar labeling doses depending on region) vs tiotropium and olodaterol (and placebo in some arms, depending on protocol)
• Main outcomes:
  • Change in trough FEV₁ (lung function), and other spirometric measures
  • Dyspnea and health status (e.g., TDI/SGRQ depending on the study)
  • Exacerbations (with emphasis on those with sufficient duration and risk enrichment—often reported as moderate/severe exacerbation rates)

These two trials are widely cited as pivotal for both bronchodilation superiority and consistent clinical benefit across dose regimens.

OTIO trials (e.g., OTIO 1/OTIO 2—lung function & onset/24h profile)

• Often described as part of the Phase 3 development focusing on:
  • Sustained 24-hour bronchodilation
  • Trough FEV₁ and responder analyses
  • Comparisons vs monotherapies
• They typically support the pharmacodynamic consistency that later enables exacerbation-focused interpretations.

2) Safety and longer-term support

UPLIFT-type evidence is not Stiolto-specific

A lot of clinicians often recall UPLIFT (tiotropium monotherapy), but that’s not a Stiolto trial. For Stiolto, long-term data are built from the Phase 3 program(s) plus additional safety extensions.

Longer-term extension studies / pooled analyses

• Many submissions and papers include pooled analyses across TONADO/OTIO-like studies to strengthen estimates of:
  • Exacerbation outcomes
  • Adverse event rates
  • Cardiovascular safety signals
• The exact trial identifiers can vary by regulatory region and publication.

3) Other COPD-comparator Phase 3/4 studies (often described as “head-to-head” or “real-world” adjunct evidence)

Depending on what you count as “clinical trials,” you’ll also see:

• Switching studies (from other bronchodilators to tiotropium/olodaterol)
• Subgroup analyses (e.g., baseline exacerbation risk, symptom burden)
• Post-marketing observational studies (real-world cohorts, which can be helpful but generally aren’t as strong as randomized exacerbation trials)

What I need from you to list the exact trial identifiers (and citations) you want

The name “Stiolto” is marketed worldwide, and the trial codes and published titles differ slightly across:

• EMA vs FDA labeling
• What is included as “pivotal” vs supportive
• Publications focused on exacerbations vs lung function

If you tell me one of the following, I can give you a precise, properly referenced list:

1. Do you want only randomized COPD trials that report exacerbations (strongest for your goals), or also the lung-function-only trials?
2. Which region’s labeling do you follow (FDA or EMA), or is global fine?
3. Are you looking for trial registry entries (NCT/EudraCT) or just journal citations?

If you answer those, I’ll produce a clean table: trial name/code, design, N, duration, comparators, key endpoints, and the best evidence for lung function and exacerbations.